Association médicamenteuse And NotR. Grondin
List of bibliographic references
Number of relevant bibliographic references: 14.| Ident. | Authors (with country if any) | Title |
|---|---|---|
| 000A80 | Richard Camicioli [États-Unis, Canada] ; Eric Lea [États-Unis] ; John G. Nutt [États-Unis] ; Gary Sexton [États-Unis] ; Barry S. Oken [États-Unis] | Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: A pilot study |
| 000B13 | ABDALLAH HADJ TAHAR [Canada] ; Anna Ekesbo [Suède] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Kjell A. Svensson [États-Unis] ; Joakim Tedroff [Suède] ; Paul J. Bedard [Canada] | Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys |
| 000B26 | Oksana Suchowersky [États-Unis, Canada] ; Peter Bailey ; E. Pourcher ; Lynne Bulger ; Giovanni Facciponte | Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD |
| 000B46 | D. J. Chong [Canada] ; O. Suchowersky [Canada] ; C. Szumlanski [États-Unis] ; R. M. Weinshilboum [États-Unis] ; R. Brant [Canada] ; N. R. C. Campbell [Canada] | The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's Disease |
| 000D53 | I. H. Richard [États-Unis] ; R. Kurlan [États-Unis] ; C. Tanner [États-Unis] ; S. Factor [États-Unis] ; J. Hubble [États-Unis] ; O. Suchowersky [Canada] ; C. Waters [États-Unis] | Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease |
| 000D85 | D. J. Doudet [Canada] ; G. L. Y. Chan [Canada] ; J. E. Holden [États-Unis] ; K. S. Morrison [Canada] ; R. J. Wyatt [États-Unis] ; T. J. Ruth [Canada] | Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-dopa trapping in MPTP-induced Parkinsonism in monkeys |
| 000E66 | C. Gagnon [Canada] ; B. Gomez-Mancilla ; R. Markstein ; P. J. Bedard ; T. Di Paolo [Canada] | Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys : regional changes of brain dopamine receptors |
| 000F57 | M. Guttman [Canada] ; G. Leger ; A. Reches ; A. Evans ; H. Kuwabara ; J. M. Cedarbaum ; A. Gjedde | Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa |
| 000F92 | B. Gomez-Mancilla [Canada] ; R. Boucher ; P. J. Bedard | Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of Parkinsonism |
| 001030 | B. Gomez-Mancilla [Canada] ; R. Boucher ; P. J. Bedard | Effect of clonidine and atropine on rest tremor in the MPTP monkey model of parkinsonism |
| 001048 | N. R. C. Campbell ; D. Rankine ; A. E. Goodridge ; B. B. Hasinoff ; M. Kara | Sinemet-ferrous sulphate interaction in patients with Parkinson's disease |
| 001063 | C. Rouillard ; P. J. Bedard ; T. Di Paolo | Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393 |
| 001147 | H. A. Robertson ; G. S. Robertson | Hypothesis. Combined L-dopa and bromocriptine therapy for Parkinson's disease: a proposed mechanism of action |
| 001176 | E. Lau ; K. Waterman ; R. Glover ; M. Schulzer ; D. B. Calne | Effect of antacid on levodopa therapy |
| This area was generated with Dilib version V0.6.29. |  |